About Akero Therapeutics, Inc.
https://www.akerotx.comAkero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health.
CEO
Andrew Cheng
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 31
Most Recent Analyst Grades
B of A Securities
Buy
Citigroup
Buy
UBS
Buy
Wolfe Research
Peer Perform
HC Wainwright & Co.
Neutral
Jefferies
Hold
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
JANUS HENDERSON GROUP PLC
Shares:6.28M
Value:$343.22M
ATP LIFE SCIENCE VENTURES, L.P.
Shares:5.83M
Value:$318.62M
GENERAL ATLANTIC, L.P.
Shares:5.73M
Value:$313.36M
Summary
Showing Top 3 of 292
About Akero Therapeutics, Inc.
https://www.akerotx.comAkero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $90.24M ▲ | $-81.57M ▼ | 0% | $-0.99 ▼ | $-80.47M ▼ |
| Q2-2025 | $0 | $80.87M ▼ | $-70.5M ▲ | 0% | $-0.86 ▲ | $-69.33M ▲ |
| Q1-2025 | $0 | $80.88M ▲ | $-70.72M ▼ | 0% | $-0.9 ▲ | $-69.57M ▼ |
| Q4-2024 | $0 | $78.03M ▼ | $-70.02M ▲ | 0% | $-0.99 ▲ | $-68.81M ▲ |
| Q3-2024 | $0 | $81.7M | $-72.7M | 0% | $-1.05 | $-71.46M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $737.83M ▼ | $1.01B ▼ | $47.94M ▼ | $957.64M ▼ |
| Q2-2025 | $742.32M ▲ | $1.11B ▼ | $83.33M ▲ | $1.03B ▼ |
| Q1-2025 | $686.29M ▼ | $1.16B ▲ | $72M ▼ | $1.08B ▲ |
| Q4-2024 | $743.08M ▲ | $825.89M ▲ | $75.77M ▼ | $750.11M ▲ |
| Q3-2024 | $717.25M | $817.55M | $79.22M | $738.33M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-81.57M ▼ | $-67.17M ▼ | $56.78M ▼ | $-34.03M ▼ | $-44.42M ▼ | $-67.17M ▼ |
| Q2-2025 | $-70.5M ▲ | $-48.25M ▲ | $79.34M ▲ | $3.43M ▼ | $34.53M ▲ | $-48.25M ▲ |
| Q1-2025 | $-70.72M ▼ | $-67.66M ▼ | $-482.18M ▼ | $395.53M ▲ | $-154.32M ▼ | $-67.66M ▼ |
| Q4-2024 | $-70.02M ▲ | $-67.09M ▲ | $15.27M ▼ | $75.99M ▲ | $24.17M ▲ | $-67.09M ▲ |
| Q3-2024 | $-72.7M | $-70.42M | $73.07M | $3.07M | $5.71M | $-70.42M |
CEO
Andrew Cheng
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 31
Most Recent Analyst Grades
B of A Securities
Buy
Citigroup
Buy
UBS
Buy
Wolfe Research
Peer Perform
HC Wainwright & Co.
Neutral
Jefferies
Hold
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
JANUS HENDERSON GROUP PLC
Shares:6.28M
Value:$343.22M
ATP LIFE SCIENCE VENTURES, L.P.
Shares:5.83M
Value:$318.62M
GENERAL ATLANTIC, L.P.
Shares:5.73M
Value:$313.36M
Summary
Showing Top 3 of 292